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Abstract
Background: Obesity is a worldwide epidemic, and severe obesity is a risk factor for many diseases, including diabetes,
heart disease, stroke, and some cancers. Endocannabinoid system (ECS) signaling in the brain and peripheral tissues is
activated in obesity and plays a role in the regulation of body weight. The main research question here was whether
quantitative measurement of plasma endocannabinoids, anandamide, and related N-acylethanolamines (NAEs), combined
with genotyping for mutations in fatty acid amide hydrolase (FAAH) would identify circulating biomarkers of ECS activation
in severe obesity.
Methodology/Principal Findings: Plasma samples were obtained from 96 severely obese subjects with body mass index
(BMI) of $40 kg/m
2, and 48 normal weight subjects with BMI of #26 kg/m
2. Triple-quadrupole mass spectroscopy methods
were used to measure plasma ECS analogs. Subjects were genotyped for human FAAH gene mutations. The principal
analysis focused on the FAAH 385 CRA (P129T) mutation by comparing plasma ECS metabolite levels in the FAAH 385
minor A allele carriers versus wild-type C/C carriers in both groups. The main finding was significantly elevated mean plasma
levels of anandamide (15.161.4 pmol/ml) and related NAEs in study subjects that carried the FAAH 385 A mutant alleles
versus normal subjects (13.361.0 pmol/ml) with wild-type FAAH genotype (p=0.04), and significance was maintained after
controlling for BMI.
Conclusions/Significance: Significantly increased levels of the endocannabinoid anandamide and related NAEs were found
in carriers of the FAAH 385 A mutant alleles compared with wild-type FAAH controls. This evidence supports
endocannabinoid system activation due to the effect of FAAH 385 mutant A genotype on plasma AEA and related NAE
analogs. This is the first study to document that FAAH 385 A mutant alleles have a direct effect on elevated plasma levels of
anandamide and related NAEs in humans. These biomarkers may indicate risk for severe obesity and may suggest novel ECS
obesity treatment strategies.
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Introduction
Endocannabinoids (ECs) are a family of polyunsaturated fatty
acid derivatives that function as lipid signaling molecules by acting
as endogenous ligands at the two known cannabinoid receptors
(CBRs), CB1 and CB2, present in the nervous system and
peripheral organs of many living species [1–4]. The endocannabi-
noid system (ECS) is highly developed in mammals, especially in
humans, and the physiology and pharmacology of the ECS have
been the subject of several comprehensive reviews in recent years
[5–7]. The most well-studied of the ECs are the fatty acid amides
(FAAs) represented by N-arachidonyl ethanolamine (AEA) or
anandamide, N-palmitoyl ethanolamine (PEA), N-oleoyl ethanol-
amine (OEA) and related N-acylethanolamine (NAE) derivatives
together with the esters of arachidonic acid including 2-arachidonyl
glycerol (2-AG) as well as other lipid signaling molecules acting at
CBRs [2,7–10].Someof these ECsare known to modulate a variety
of physiological functions including synaptic transmission, immune
function, nociception, fertility, and cardiovascular function, in
addition to nervous system development, and are involved in many
pathophysiological disease processes [5,7,11].
The complex biosynthetic and enzymatic degradation pathways
for these ECS signaling molecules are currently being investigated
as potentially selective disease treatment targets [6,11], particularly
fatty acid amide hydrolase (FAAH) and monoglyceride lipase
(MGLL), which are the principal inactivating enzymes for FAAs
and 2-AG. There is an increasing body of data on endocanna-
binoid control of energy homeostasis and recent evidence for ECS
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become apparent that human obesity is associated with activation
of the ECS and with increased levels of ECs in many tissues, as
well as in the circulation [17] However, the underlying molecular
mechanisms of ECS dysregulation in obesity need clarification to
better understand ECS risk factors in obesity and to develop novel
selective treatment strategies.
Current concepts in this field indicate that body weight and fat
metabolism are influenced by complex ECS regulatory mechanisms
that modulate energybalance,feedingbehaviorandperipherallipid
metabolism [18,19]. The ECS comprises one of the most important
weight regulatory systems in humans, since endocannabinoids have
numerous effects on energy homeostasis by activating cannabinoid
receptors throughout the nervous system and in the periphery [8]
together with modulation of other downstream energy regulating
molecules. In the mammalian brain, ECs modulate appetite via
leptin-regulated circuits in the lateral hypothalamus or by direct
activation of the mesolimbic dopamine ‘‘reward’’ pathways for food
intake and thus may increase feeding behavior in animal models of
obesity [19]. In mammalian peripheral tissues, ECs may have direct
effects, for example in adipose tissue where CB1 receptors are
located and ECS biosynthetic and degradative enzymes are
expressed [20,21], in the liver where ECs promote hepatic
lipogenesis [12], in the intestine where OEA [22], the monounsat-
urated analogue of anandamide has the opposite or anorexic effect
of decreasing food intake and body weight in animal models [15], as
well as ECS effects in other tissues such as skeletal muscle [16] and
endocrine pancreas [23].
Recent investigations have demonstrated activation of the
peripheral ECS in human obesity and type II diabetes [24] as
well as increased circulating plasma AEA levels in young women
with binge eating disorder [25]. Increased plasma AEA and 2-AG
levels have been found in obese menopausal women compared to
lean women of similar age [26]. A study in a human visceral
obesity disorder in men has shown elevated plasma fasting levels of
2-AG but not AEA as measured by liquid chromatography-mass
spectroscopy [27]. Also, a strong negative correlation has been
found between FAAH expression in adipose tissue and circulating
ECs [26]. Other studies of plasma AEA and 2-AG levels have
shown no relationship with obesity or body fat distribution [17],
but these findings may be related to differences in methodology or
obesity phenotypes in the study cohorts. Importantly, the
pathophysiological role of circulating endocannabinoids as risk
factors for obesity remains to be elucidated.
The overall aim of the present study was to investigate
circulating biomarkers of ECS activation in severely obese subjects
compared to normal weight controls using highly sensitive triple-
quadrupole mass spectroscopy plasma quantification methods,
combined with genotyping for common mutations in the genes
encoding the endocannabinoid and fatty acid amide inactivating
enzymes FAAH and MGLL. This aim is based on our previous
reports that showed an association of the common human FAAH
385 CRA (P129T)non-synonymous mutation with overweight
and obesity [28] and biochemical evidence of approximately 50%
reduced cellular expression and activity of mutant human P129T
FAAH [29]. This study achieved the aim of identifying both plasma
and FAAH gene ECS biomarkers of severe obesity that have the
potential to be clinically useful if confirmed by larger studies.
Methods
Objectives
The objective of this study was to investigate readily available
circulating biomarkers of ECS activation in severely obese subjects
compared to normal weight subjects by combining accurate
measurement of plasma endocannabinoid levels with SNP
genotyping in critical ECS inactivating enzymes. The main
hypothesis herein based on previous studies was that plasma levels
of anandamide and related NAEs would be elevated in severely
obese carriers of the FAAH 385 A alleles compared to normal
weight wild-type FAAH carriers. This evidence could further
support ECS activation in a sub-type of severely obese individuals
and may indicate novel ECS treatment targets in severe obesity.
Participants
Samples and linked biometric data used in this study were
obtained from the rimonabant (Acomplia) CRESCENDO study
(http://clinicaltrials.gov/ct/show/NCT00263042), a cardiovascu-
lar outcomes trial to assess the efficacy of the CB1 receptor
antagonist, rimonabant (Acomplia), in reducing the risk of heart
attack, stroke, or cardiovascular death in abdominally obese
individuals and comprised 18,671 randomized and treated
subjects and was conducted by Sanofi-Aventis. Subjects and
samples for this study were from a subset of 3101 subjects who
volunteered with separate written informed consent for the
CRESCENDO Genomic Substudy cohort. A subset of the
substudy were selected for this ECS study based on BMI (150
with BMI,30 and 150 with BMI.40). Severely obese subjects for
this ECS metabolite and genomics study were selected from the
Genomic Substudy cohort based on a body mass index (BMI) of
40 kg/m
2 to 60 kg/m
2 and waist circumference of greater or
equal to 140 cm in men and 131 cm in women. Normal weight
controls were included based on a BMI of less than 26 kg/m
2 and
a waist circumference of less than or equal to 100 cm in men and
90 cm in women. To reduce false-positive findings due to differing
genetic backgrounds, and since Whites were highly represented in
the patient population sampled, the study was limited to male and
female Whites, ranging in age from 55 to 77. All study participants
and data were anonymous and biometric data were linked to each
plasma and DNA sample by unique study code (see Dataset S1).
The anonymous biometric data and the subjects’ samples were
obtained with broad informed consent approved by the Institu-
tional Review Board (IRB)/EC for the site and use of anonymous
samples in the current study received additional approval from the
Scripps IRB.
Procedures: Plasma Endocannabinoid and NAE Analysis
Whole blood samples were collected in evacuated glass tubes
containing EDTA. Samples were centrifuged to separate plasma
from blood cells and plasma was withdrawn and stored in 1 ml
aliquots at 280uC prior to plasma lipid extraction. For each
sample, 0.5 ml plasma was added to a glass vial containing 2.0 ml
chloroform (CHCl3), 1.0 ml methanol (MeOH) and 0.5 ml (1%
v/v) formic acid. To this mixture were added aliquots of 10 pmol
D5-2-arachidonlyglycerol (2-AG) and 5 pmol D8-arachidon-
lyethanolamine (AEA). Vial contents were vortex mixed for 30
seconds and centrifuged at 10uC (14006g for 10 minutes). The
organic layer was carefully removed avoiding the aqueous layer
and dried under a stream of nitrogen (N2) gas. The lipid layer was
then re-solubilized in 100 microliters of 2:1 CHCl3:CH3OH.
Quantitative analysis of endocannabinoids and NAE analogues
using the deuterated standards for AEA and 2-AG together with
calculation of the other EC analogues was based on a ratio to the
deuterated standards [30] and was performed on the Agilent 6410
Triple Quadrupole Liquid Chromatography-Mass Spectroscopy
(TQMS) instrument using positive ion analysis mode. For each
sample, 20 microliters of re-solubilized plasma lipids were injected
into the TQMS instrument and EC congeners were measured by
ECS Obesity Biomarkers
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tions: 348.62 (AEA), fragmentation energy=8, and 379.287 (2-
AG), fragmentation energy=11. Chromatography was performed
using the following solvents: A - 95:5:0.1 H20:methanol:formic
acid and B – 60:35:5:0.1 isopropanol:methanol:H2O:formic acid.
Lipids were injected into a 5 microcentimeter C
18 column
(5064.6 mm) from Phenomenex (Torrance, CA) and eluted with
a 10 minute solvent B gradient from 60% to 100%. Values for
each endocannabinoid and NAE analogue were subsequently
calculated using ratios to the deuterated internal standards to
calculate absolute concentrations, expressed as picomoles (pmol) of
EC metabolite per ml of plasma similar to current methods [30].
Procedures: FAAH and MAGL SNP Genotyping Methods
and Study Subjects
Genotyping of the SNPs in the FAAH (GeneID 2166) and
MGLL (GeneID 11343) from dbSNP was performed using the
Sequenom platform. The major allele frequencies were deter-
mined in all 300 obese and normal subjects, using the Sequenom
data for detection of 4 common SNPs in FAAH and 16 in MGLL
(data not shown). To reduce false-positive findings due to differing
genetic backgrounds, the same patient population used for the EC
metabolite analysis was sampled and only male and female Whites
were included, as noted above.
Procedures: Statistical Methods
The apriori or pre-study power calculation to detect a true
association in this study was based upon estimations from data
reported for measurement of anandamide levels in humans in a
clinical trial [31]. Using a standard deviation (SD) for anandamide
of approximately 4 pmoles/ml, the power was 0.9 to detect a
difference of 2.2 pmoles/ml (standardized difference 0.53) and
power of 0.8 to detect a difference of 1.8 pmoles/ml (standardized
difference 0.45) at alpha=0.05 with an expected total sample size
of 150.
The distribution of each metabolite was assessed for outliers and
normality. Log transformation of data resulted in normal
distributions for all EC analogues. Stratification revealed no
significant differences in mean metabolite levels by age and sex
and these variables were thus not included in further analyses.
Geometric means of each metabolite were compared between
BMI groups using the t-test. Frequencies of the FAAH genotype
were compared between the severely obese and normal weight
groups using the Fisher’s exact test. Geometric mean levels of EC
analogues were compared between FAAH genotype groups
(carriers of the minor ‘‘A’’ allele compared with subjects with
the wild type genotype C/C) in both BMI groups combined using
the t-test and stratified by BMI group using 2-Way ANOVA.
Normal weight wild-type FAAH subjects were compared with
severely obese carriers of the FAAH 385 mutant A allele using 1-
Way ANOVA with Dunnett’s Correction for multiple compari-
sons. A two-sided p-value ,0.05 was considered statistically
significant.
Ethics
Participants in this study initially gave broad written informed
consent for collection and analysis of plasma and DNA for the
Sanofi-Aventis CRESCENDO Genomic Substudy. In this study of
EC analogues, all subjects were anonymous and identified only by
a code number linked to biometric data. Because informed
consent from strictly anonymous CRESCENDO study subjects
was not possible, the present study received an exemption for
additional written consent from the Scripps IRB.
Results
Endocannabinoid and NAE Levels
Demographic characteristics of the 96 severely obese subjects
and 48 normal weight controls included in the study are shown in
Table 1. The severely obese group had a mean age that was
approximately 5 years younger than the normal weight group
(p,0.0001). Other variables including the percentage of male
subjects (44% in severely obese vs. 35% in the normal weight
group) were not statistically different.
The baseline mean endocannabinoid and NAE levels (Table 2)
were not significantly different among the subjects in the two BMI
groups except for high LEA (p=0.04) and low DHEA (p=0.002)
plasma levels. There was a trend to elevated anandamide (AEA)
levels (p=0.06) in severely obese subjects that was not quite
significant (Table 2).
SNP Genotyping
Analysis of the FAAH and MGLL genes for common gene
variations or SNPs was completed and there were no common
variants of MGLL found in this study. The only coding variant
commonly found in the subjects in this obesity study was the FAAH
385 CRA (P129T) as previously reported [28]. In the ECS
metabolite analysis group (n=144) frequency of the mutant A/A
genotype was 7.3% in the severely obese compared to 4.2% A/A
in the normal weight group, a nearly 2 fold difference similar to
the previous study [28] that was not statistically significant here,
probably because this study was not powered to detect a significant
genotype difference.
Table 1. Demographic Characteristics of EC Metabolite Study Subjects.
Characteristic Severely Obese (n=96) Normal Weight (n=48)
Mean (SD) Range Mean (SD) Range
Age (years) 61.9 (5.8) 55–77 66.4 (6.7) 55–77
Body Mass Index (kg/m
2) 49.2 (3.2) 45–58 24.7 (1.2) 22–26
n% N%
Male 43 44.8 17 35.4
Mean (SD) Range Mean (SD) Range
Waist circumference (cm), Males 151.2 (8.1) 140–170 103.3 (0.4) 102–104
Waist circumference (cm), Females 140.7 (7.0) 131–157 93.7 (3.3) 89–100
doi:10.1371/journal.pone.0008792.t001
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P129T Mutation
To evaluate the effects of the FAAH C385A mutation on the
circulating plasma levels of endocannabinoids and NAE ana-
logues, geometric mean congener levels were compared between
carriers of the FAAH 385 mutant A allele and homozygotes for the
wild type (WT) C alleles Using the t-test comparing geometric
mean plasma metabolite levels in the two groups, there was a
significant elevation of mean anandamide (AEA) levels (p=0.04)
and related NAE levels in carriers of the FAAH 385 mutant A
alleles versus FAAH-WT carriers (Table 3.). An analysis comparing
severely obese FAAH 385 A carriers versus normal weight FAAH-
WT subject groups using 2-way ANOVA which controls for BMI
to analyze the direct effect of FAAH 385 A mutant alleles
compared to subjects with the wild-type FAAH C/C genotype also
showed significant (p,0.05)) elevation of AEA and related NAEs
(Table 4). In the 2-way ANOVA analysis (Table 4), the interaction
terms (genotype X BMI category) were not statistically significant
for any of the EC analogues listed. The findings were internally
consistent and statistically significant using multiple statistical
methods as noted. As shown in Figure 1, comparing the four
subject groups including FAAH-WT normal weight, FAAH-WT
Obese, FAAH CRA normal weight and FAAH CRA Obese,
revealed a trend toward increasing mean AEA levels with
significantly elevated AEA (p,0.05) in obese FAAH mutant A
allele carriers versus FAAH-WT normal weight subjects using 1-
Way ANOVA with Dunnett’s correction for multiple compari-
sons. This amounts to a modest but significant 1.14 fold higher
mean AEA plasma level in severely obese mutant FAAH carriers
compared to normal FAAH controls. Several other N-acylethano-
lamines related to AEA that are metabolized by FAAH, including
PEA, OEA and LEA, were also significantly elevated in severely
obese mutant carriers versus normal controls (see Dataset S1).
Plasma levels of the endocannabinoid 2-AG, which is not
metabolized by FAAH, showed no difference comparing severely
obese and normal subjects (Tables 3 and 4).
Discussion
The principal new findings of this study were that subjects with
the FAAH 385 A mutant alleles controlling for BMI had modest
but significant elevation (p=0.04) of AEA and related NAEs
(Table 3; Figure 1) There was also modest but significantly
elevated (p,0.05) circulating mean plasma levels of anandamide
(AEA) in severely obese carriers of the FAAH 385 mutant A alleles
compared to normal BMI subjects with the wild-type FAAH
genotype Table 4; Figure 1). In Figure 1, there is the appearance
of elevated AEA levels in several groups but only the comparison
of the control FAAH-WT normal weight subjects with the FAAH
385 A carrier obese was statistically significant (p,0.05). Because
plasma levels of N-acylethanolamine analogues related to AEA,
including PEA, OEA and LEA, are significantly elevated in
severely obese carriers of the mutant FAAH 385 A alleles, this
supports the concept of a functional FAAH enzyme mutation in
subjects with FAAH 385 CRA SNPs. Taken together, these
findings provide further evidence of activation of the ECS in
severely obese subjects with the FAAH 385 CRA mutation.
Despite the relatively small subject cohort, tight plasma ranges and
statistical significance (Figure 1) was achieved by using highly
sensitive triple quadrupole mass spectroscopy methods. All
statistical methods using both the original dataset and log-
transformed dataset confirmed the internal and external validity
of this study. These findings are statistically robust with significant
Table 2. Mean plasma ECS analogue levels (picomoles/ml) by body mass index (BMI).
Metabolite Severely Obese n=96 Normal Weight n=48 p**
Mean* pmol/ml (95% CI) Mean* pmol/ml (95% CI)
AEA Anandamide arachidonylethanolamide 14.5 (13.6, 15.6) 12.8 (11.4, 14.5) 0.06
2AG 2-arachidonylglycerol 5.4 (4.8, 6.1) 5.6 (4.6, 6.8) 0.73
C22:6 DHEA Docosahexaenoylethanolamine 7.5 (7.0, 8.1) 9.2 (8.3, 10.1) 0.002
C16:0 PEA Palmitoylethanolamine 215.3 (203.8, 227.4) 213.3 (190.1, 239.3) 0.87
C18:0 SEA Stearoylethanolamine 76.6 (71.4, 82.1) 80.1 (70.5, 92.7) 0.44
C18:1 OEA Oleoylethanolamine 118.6 (111.2, 126.6) 107.9 (97.2, 119.8) 0.11
C18:2 LEA Linoleoylethanolamine 44.7 (41.5, 48.0) 38.9 (34.9, 43.4) 0.04
CI=confidence interval.
*geometric mean based on log-transformed data.
**Student’s t-test.
doi:10.1371/journal.pone.0008792.t002
Table 3. T-test Comparison between FAAH C385A carriers and
wild-type subjects with BMI groups combined.
Metabolite
FAAH C385A
(P129T)Genotype
Geometric Mean
(95%) CI p-value
AEA C/C 13.3 (12.3, 14.4) 0.04
A/C + A/A 15.1 (13.7, 16.8)
2-AG C/C 5.5 (4.8, 6.3) 0.97
A/C + A/A 5.5 (4.7, 6.4)
C22:6 DHEA C/C 7.8 (7.2, 8.3) 0.09
A/C + A/A 8.6 (7.7, 9.6)
C16:0 PEA C/C 198.7 (189.7, 208.1) 0.0006
A/C + A/A 229.8 (213.3, 247.5)
C18:0 SEA C/C 71.7 (67.5, 76.1) 0.004
A/C + A/A 83.6 (76.3, 91.6)
C18:1 OEA C/C 108.0 (100.5, 115.9) 0.003
A/C + A/A 128.0 (118.0, 138.9)
C18:2 LEA C/C 40.9 (37.9, 44.2) 0.08
A/C + A/A 45.8 (41.4, 50.6)
doi:10.1371/journal.pone.0008792.t003
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AEA to p=0.003 in the case of OEA (Tables 4 and Figure 1).
Although there is a modest 1.14 fold elevation of mean plasma
AEA levels in severely obese mutant FAAH carriers, the findings
are nevertheless statistically significant in this careful case-
controlled study.
These findings are noteworthy because endocannabinoid
signaling molecules like AEA are known to regulate food intake
and fat metabolism in humans. The role of endocannabinoid
system dysregulation as a risk factor in the development of obesity
has been the subject of considerable recent interest [13,15,17,26].
Activation of the ECS in obesity [17] has the potential to identify
clinically useful biomarkers of ECS risk factors that may contribute
to severe obesity through appetite stimulation, high fat intake and
fat metabolism.
In the present study, we present the first evidence of a direct
effect of FAAH 385 A mutant alleles on elevated mean basal levels
of anandamide (AEA) in carriers of the FAAH P129T mutation.
This is substantiated by demonstration of several of elevated N-
acylethanolamine analogues related to AEA that are also
metabolized by FAAH. In this study, the FAAH 385 CRA
(P129T) mutant genotype, which is the principal catabolic enzyme
of many N-acyl ethanolamine ECS signaling molecules, has the
same approximately 2-fold prevalence (7.3% vs. 4%) in severely
obese subjects compared to normal BMI subjects observed in a
previous study (28). Among both obese and normals, carriers of
the FAAH 385 minor A alleles had higher levels of AEA and other
NAEs, except 2-AG which is not metabolized by FAAH. Likewise,
all endocannabinoid levels were positively correlated with each
other except 2-AG (Table 4). Of particular interest is the
significant (p,0.05) but modest elevation of AEA in subjects with
the FAAH 385 mutant A alleles (Figure 1), since AEA activates the
CB1 receptor and has the potential to stimulate appetite and
feeding behavior as well as modulate several metabolic functions
including fatty acid metabolism and contributes to diet-induced
obesity [12,16].
At the present time, there are four human clinical studies
investigating the association of the functional FAAH P129T
mutation with obesity. In two larger studies, one demonstrated a
significant association of the FAAH P129T genotype variant with
overweight and obesity [28] and one study showed no significant
association of this variant with fat accumulation phenotypes [32].
In two smaller clinical studies, one confirmed the significant over-
representation of the FAAH 385 A alleles in overweight/obese
Figure 1. Geometric mean Anandamide (AEA) levels by BMI
group and FAAH genotype. Error bars indicate 95% confidence
intervals for geometric means. *p,0.05 compared with FAAH wildtype
normal weight controls using 1-way ANOVA with Dunnett’s correction
for multiple comparisons but p.0.05 for all other pairwise comparisons.
doi:10.1371/journal.pone.0008792.g001
Table 4. Comparison of Mean Plasma ECS Analogue Levels by FAAH 385 Genotype Controlling for BMI.
BMI Group
Metabolite
FAAH (385)
P129TGenotype Low BMI High BMI
p-value for A carriers vs. wildtype
controlling for BMI group (2-Way ANOVA)
AEA C/C 11.8 (10.0, 13.9) 14.0 (12.9, 15.3) 0.04
A/C + A/A 14.4 (12.0, 17.4) 15.6 (13.7, 17.7)
2-AG C/C 5.4 (4.0, 7.3) 5.5 (4.7, 6.4) 0.94
A/C + A/A 5.9 (4.5, 7.6) 5.2 (4.3, 6.4)
C22:6 DHEA C/C 9.0 (7.9, 10.1) 7.2 (6.6, 7.8) 0.08
A/C + A/A 9.4 (8.0, 11.2) 8.1 (7.0, 9.4)
C16:0 PEA C/C 195.0 (173.5, 219.1) 200.3 (191.4, 209.6) 0.005
A/C + A/A 220.3 (191.3, 253.7) 235.8 (216.0, 257.7)
C18:0 SEA C/C 75.0 (65.8, 85.5) 70.3 (65.7, 75.2) 0.02
A/C + A/A 80.0 (67.6, 94.8) 85.9 (76.9, 95.9)
C18:1 OEA C/C 96.5 (83.7, 111.3) 113.4 (104.6, 123.0) 0.003
A/C + A/A 126.2 (110.2, 144.5) 129.1 (116.0, 143.7)
C18:2 LEA C/C 37.4 (32.1, 43.4) 42.6 (39.0, 46.6) 0.08
A/C + A/A 41.2 (34.9, 48.7) 48.8 (43.0, 55.4)
doi:10.1371/journal.pone.0008792.t004
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with metabolic syndrome found no significant association with the
FAAH P129T variant after correction for multiple comparisons
[34]. Thus, more clinical studies with comparable subject cohorts
are needed to evaluate the significance of the association of the
FAAH 385 A mutant alleles with overweight and obesity. Since the
relatively common FAAH P129T mutation has been associated
with obesity in some studies [28,33], it is possible that other rare
FAAH variants or MGLL variants may also contribute to ECS tonic
activation in severely obese individuals. These significant AEA
elevations suggest that mean basal plasma ECS metabolite levels
measured with sensitive techniques and stratified by metabolizing
FAAH enzyme genotype may be a reliable indicator of biologic
dysregulation in the endocannabinoid system.
This study is the first to document that the FAAH 385 A mutant
alleles directly affect elevated plasma levels of AEA and related
NAEs and suggests that using biomarkers including AEA, PEA,
OEA and LEA plasma levels combined with genotyping for the
minor FAAH 385 variant A allele may identify a new ECS-related
obesity phenotype with a higher risk for severe obesity. Larger
clinical obesity studies of plasma endocannabinoid and NAE levels
correlated with FAAH P129T genotype are needed in normal,
mildly overweight and severely obese subjects to confirm the
presence of linked plasma and FAAH gene ECS biomarkers for the
risk of severe obesity since independent confirmation could, in
turn, lead to more selective endocannabinoid or EC analogue
treatment strategies.
Supporting Information
Dataset S1
Found at: doi:10.1371/journal.pone.0008792.s001 (0.07 MB
XLS)
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